The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum

Robert P Finger, Eva Fenwick, Manjula Marella, Peter Charbel Issa, Hendrik P N Scholl, Frank G Holz, Ecosse L Lamoureux, Robert P Finger, Eva Fenwick, Manjula Marella, Peter Charbel Issa, Hendrik P N Scholl, Frank G Holz, Ecosse L Lamoureux

Abstract

Objective: To investigate the impact of pseudoxanthoma elasticum (PXE), a rare hereditary disease of concurrent vision impairment (VI) and cardiovascular complications (CVCs), on vision-related (VRQoL) and health-related quality of life (HRQoL).

Methods: VRQoL and HRQoL were assessed using the Impact of Vision Impairment (IVI) questionnaire and the Short Form Health Survey (SF-36) in 107 PXE patients. Patients were stratified into four groups: A = no VI or CVC; B = CVCs only; C = VI only; and D = both VI and CVCs.

Results: Following Rasch analysis, the IVI was found to function as a vision-specific functioning and emotional well-being subscale, and the SF-36 as a health-related physical functioning and mental health subscale. The presence of VI and CVC were significant predictors of vision-specific functioning and emotional well-being (p < 0.001), with a clinically meaningful decrement in vision-specific functioning in patients with VI. No associations were found for the SF-36 Physical Functioning and Mental Health scores between any groups.

Conclusions: Vision impaired patients with PXE report significantly poorer vision-specific functioning than PXE patients without VI. In contrast, the relative impact of PXE on reported general HRQoL was much less. Our results suggest that vision impairment has the larger impact on QoL in this sample.

References

    1. Finger RP, Charbel Issa P, Ladewig MS, Gotting C, Szliska C, Scholl HP, Holz FG. Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol. 2009;54:272–285. doi: 10.1016/j.survophthal.2008.12.006.
    1. Challenor VF, Conway N, Monro JL. The surgical treatment of restrictive cardiomyopathy in pseudoxanthoma elasticum. Br Heart J. 1988;59:266–269. doi: 10.1136/hrt.59.2.266.
    1. Fukuda K, Uno K, Fujii T, Mukai M, Handa S. Mitral stenosis in pseudoxanthoma elasticum. Chest. 1992;101:1706–1707. doi: 10.1378/chest.101.6.1706.
    1. Lebwohl M, Halperin J, Phelps RG. Brief report: occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. N Engl J Med. 1993;329:1237–1239. doi: 10.1056/NEJM199310213291705.
    1. Lebwohl MG, Distefano D, Prioleau PG, Uram M, Yannuzzi LA, Fleischmajer R. Pseudoxanthoma elasticum and mitral-valve prolapse. N Engl J Med. 1982;307:228–231. doi: 10.1056/NEJM198207223070406.
    1. Scheie HG, Hogan TF Jr. Angioid streaks and generalized arterial disease. AMA Arch Ophthalmol. 1957;57:855–868. doi: 10.1001/archopht.1957.00930050869010.
    1. Cailleux N, Hachulla E, Perez-Cousin M, Labalette P, Lecomte-Houcke M. Pseudoxanthoma elasticum: a rare cause of leg artery diseases in young adults. J Mal Vasc. 1997;22:51–55.
    1. Charbel Issa P, Finger RP, Gotting C, Hendig D, Holz FG, Scholl HP. Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology. 2010;117:1406–1414. doi: 10.1016/j.ophtha.2009.11.008.
    1. Charbel Issa P, Finger RP, Holz FG, Scholl HP. Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterisation of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci. 2009.
    1. West SK, Munoz B, Rubin GS, Schein OD, Bandeen-Roche K, Zeger S, German S, Fried LP. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury Eye Evaluation. Invest Ophthalmol Vis Sci. 1997;38:72–82.
    1. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol. 1999;128:45–53. doi: 10.1016/S0002-9394(99)00169-5.
    1. Bach JP, Riedel O, Pieper L, Klotsche J, Dodel R, Wittchen HU. Health-Related Quality of Life in Patients with a History of Myocardial Infarction and Stroke. Cerebrovasc Dis. pp. 68–76.
    1. Borowiak E, Kostka T. Influence of chronic cardiovascular disease and hospitalisation due to this disease on quality of life of community-dwelling elderly. Qual Life Res. 2006;15:1281–1289. doi: 10.1007/s11136-006-0058-0.
    1. Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg. pp. 843–849. 849 e841.
    1. Lamoureux EL, Pallant JF, Pesudovs K, Hassell JB, Keeffe JE. The Impact of Vision Impairment Questionnaire: an evaluation of its measurement properties using Rasch analysis. Invest Ophthalmol Vis Sci. 2006;47:4732–4741. doi: 10.1167/iovs.06-0220.
    1. Lamoureux EL, Pallant JF, Pesudovs K, Rees G, Hassell JB, Keeffe JE. The impact of vision impairment questionnaire: an assessment of its domain structure using confirmatory factor analysis and rasch analysis. Invest Ophthalmol Vis Sci. 2007;48:1001–1006. doi: 10.1167/iovs.06-0361.
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med. 1995;41:1359–1366. doi: 10.1016/0277-9536(95)00115-N.
    1. Keeffe JE, McCarty CA, Hassell JB, Gilbert AG. Description and measurement of handicap caused by vision impairment. Aust N Z J Ophthalmol. 1999;27:184–186. doi: 10.1046/j.1440-1606.1999.00179.x.
    1. Weih LM, Hassell JB, Keeffe J. Assessment of the impact of vision impairment. Invest Ophthalmol Vis Sci. 2002;43:927–935.
    1. Lamoureux EL, Hassell JB, Keeffe JE. The determinants of participation in activities of daily living in people with impaired vision. Am J Ophthalmol. 2004;137:265–270. doi: 10.1016/j.ajo.2003.08.003.
    1. Finger R, Fenwick E, Marella M, Petrak M, Holz F, Chiang P, Lamoureux E. The impact of vision impairment on vision-specific quality of life in Germany. under review. 2011.
    1. Ware JE Jr, Kosinski M, Gandek B, Aaronson NK, Apolone G, Bech P, Brazier J, Bullinger M, Kaasa S, Leplege A. et al.The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1159–1165. doi: 10.1016/S0895-4356(98)00107-3.
    1. Gandek B, Ware JE Jr, Aaronson NK, Alonso J, Apolone G, Bjorner J, Brazier J, Bullinger M, Fukuhara S, Kaasa S. et al.Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1149–1158. doi: 10.1016/S0895-4356(98)00106-1.
    1. Wagner AK, Gandek B, Aaronson NK, Acquadro C, Alonso J, Apolone G, Bullinger M, Bjorner J, Fukuhara S, Kaasa S. et al.Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:925–932. doi: 10.1016/S0895-4356(98)00083-3.
    1. Bullinger M. [Assessment of health related quality of life with the SF-36 Health Survey] Rehabilitation (Stuttg) 1996;35:XVII–XXVII. quiz XXVII-XXIX.
    1. Wang HM, Beyer M, Gensichen J, Gerlach FM. Health-related quality of life among general practice patients with differing chronic diseases in Germany: cross sectional survey. BMC Public Health. 2008;8:246. doi: 10.1186/1471-2458-8-246.
    1. Linacre JM. A user's guide to Winsteps/Ministeps Rasch-Model Pograms. Chicago, IL: MESA Press; 2005.
    1. Linacre JM. Winsteps Rasch measurement computer program. Book Winsteps Rasch measurement computer program. 2008. (Editor ed.^eds.). City: .
    1. Bond TG, Fox CM. Applying the Rasch model: Fundamental Measurement in the Human Sciences. London: Lawrence Erlbaum Associates; 2001.
    1. Pesudovs K, Burr JM, Harley C, Elliott DB. The development, assessment, and selection of questionnaires. Optom Vis Sci. 2007;84:663–674. doi: 10.1097/OPX.0b013e318141fe75.
    1. Pierce CA, Block RA, Aguinis H. Cautionary Note on Reporting Eta-Squared Values from Multifactor ANOVA Designs. Educational and Psychological Measurement. 2004;64:916–924. doi: 10.1177/0013164404264848.
    1. Linacre JM. Sample Size and Item Calibration Stability. Rasch Measurement Transactions. 1994;7:328.
    1. Sloan J. Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. COPD. 2005;2:57–62. doi: 10.1081/COPD-200053374.
    1. Norman G, Sloan J, Wyrwich K. Interpreation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–592.
    1. Lamoureux EL, Chong E, Wang JJ, Saw SM, Aung T, Mitchell P, Wong TY. Visual impairment, causes of vision loss, and falls: the singapore malay eye study. Invest Ophthalmol Vis Sci. 2008;49:528–533. doi: 10.1167/iovs.07-1036.
    1. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116:514–520.
    1. Wynia K, Middel B, van Dijk JP, De Keyser JH, Reijneveld SA. The impact of disabilities on quality of life in people with multiple sclerosis. Mult Scler. 2008;14:972–980. doi: 10.1177/1352458508091260.
    1. Evenhuis HM, Sjoukes L, Koot HM, Kooijman AC. Does visual impairment lead to additional disability in adults with intellectual disabilities? J Intellect Disabil Res. 2009;53:19–28. doi: 10.1111/j.1365-2788.2008.01114.x.
    1. Lamoureux EL, Tai ES, Thumboo J, Kawasaki R, Saw SM, Mitchell P, Wong TY. Impact of diabetic retinopathy on vision-specific function. Ophthalmology. pp. 757–765.
    1. Gall C, Mueller I, Gudlin J, Lindig A, Schlueter D, Jobke S, Franke GH, Sabel BA. Vision- and health-related quality of life before and after vision restoration training in cerebrally damaged patients. Restor Neurol Neurosci. 2008;26:341–353.
    1. Evenhuis HM. Medical aspects of ageing in a population with intellectual disability: I. Visual impairment. J Intellect Disabil Res. 1995;39(Pt 1):19–25.
    1. Finger RP, Charbel Issa P, Ladewig M, Holz FG, Scholl HP. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol. 2008;92:483–487. doi: 10.1136/bjo.2007.129916.
    1. Jacobson AM, Rand LI, Hauser ST. Psychologic stress and glycemic control - a comparison of patients with and without proliferative diabetic retinopathy. Psychosomatic Medicine. 1985;47:372–381.
    1. Bernbaum M, Albert SG, Duckro PN. Psychosocial profiles in patients with visual impairment due to diabetic-retinopathy. Diabetes Care. 1988;11:551–557. doi: 10.2337/diacare.11.7.551.
    1. Lamoureux EL, Pallant JF, Pesudovs K, Rees G, Hassell JB, Keeffe JE. The effectiveness of low-vision rehabilitation on participation in daily living and quality of life. Invest Ophthalmol Vis Sci. 2007;48:1476–1482. doi: 10.1167/iovs.06-0610.
    1. Hinds A, Sinclair A, Park J, Suttie A, Paterson H, Macdonald M. Impact of an interdisciplinary low vision service on the quality of life of low vision patients. Br J Ophthalmol. 2003;87:1391–1396. doi: 10.1136/bjo.87.11.1391.
    1. Reeves BC, Harper RA, Russell WB. Enhanced low vision rehabilitation for people with age related macular degeneration: a randomised controlled trial. Br J Ophthalmol. 2004;88:1443–1449. doi: 10.1136/bjo.2003.037457.
    1. Castori M, Camerota F, Celletti C, Grammatico P, Padua L. Quality of life in the classic and hypermobility types of Ehlers-Danlos syndrome [corrected] Ann Neurol. pp. 145–146. author reply 146-147.
    1. Swamy BN, Chia EM, Wang JJ, Rochtchina E, Mitchell P. Correlation between vision- and health-related quality of life scores. Acta Ophthalmol. 2009;87:335–339. doi: 10.1111/j.1755-3768.2008.01203.x.
    1. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116:1496–1504.
    1. Bradley C. Importance of differentiating health status from quality of life. Lancet. 2001;357:7–8. doi: 10.1016/S0140-6736(00)03562-5.
    1. Cohen J. Statistical power analysis for the behavior sciences. 2. London: Taylor & Francis; 1988.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere